Helix Acquisition Corp. II Reports Q2 2025 Financial Results, Faces Liquidity Challenges

Helix Acquisition Corp. II reported its financial results for the second quarter of 2025, revealing a net income of $918,310 for the three months ending June 30, 2025, compared to a significantly higher net income of $2,212,536 for the same period in 2024. The company generated $2,074,999 in interest from marketable securities held in its Trust Account, which was partially offset by general and administrative expenses totaling $1,121,848. For the first half of 2025, Helix reported a net income of $430,918, down from $3,312,978 in the prior year, reflecting a substantial increase in operational costs.

The company’s total assets as of June 30, 2025, amounted to $197.4 million, a slight increase from $194.4 million at the end of 2024. However, current liabilities surged to $2.6 million from $187,515, primarily due to increased accounts payable and accrued expenses. The accumulated deficit also widened to $7.3 million from $3.7 million, indicating a growing financial strain as the company continues to prepare for its initial business combination.

Strategically, Helix Acquisition Corp. II is in the process of completing a business combination with TheRas, Inc., which operates as BridgeBio Oncology Therapeutics. This agreement, signed on February 28, 2025, includes plans for the company to migrate from the Cayman Islands to Delaware and merge with its subsidiary. The transaction is contingent upon shareholder approval and the fulfillment of customary conditions, including the requirement for a minimum amount of transaction proceeds.

Operationally, Helix has not yet commenced any revenue-generating activities, as it remains focused on identifying and negotiating potential business combinations. The company has maintained a steady count of 18,909,000 Class A ordinary shares outstanding, with 4,600,000 Class B shares also issued. As of June 30, 2025, Helix had cash reserves of $664,231, down from $1.7 million at the end of 2024, indicating a need for careful cash management as it pursues its acquisition strategy.

Looking ahead, Helix Acquisition Corp. II faces significant liquidity challenges, with management expressing concerns about its ability to sustain operations beyond one year without completing a business combination. The company has until February 14, 2026, to finalize this transaction, or it will be required to liquidate. The management team is actively working to secure the necessary funding and approvals to ensure the successful completion of the proposed merger with BridgeBio Oncology Therapeutics.